PMID- 30464617
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 10
DP  - 2018
TI  - Interleukin-18 promoter genotype is associated with the risk of nasopharyngeal 
      carcinoma in Taiwan.
PG  - 5199-5207
LID - 10.2147/CMAR.S179367 [doi]
AB  - BACKGROUND: The incidence rate of nasopharyngeal carcinoma (NPC) has been 
      documented to be high in Southeast Asia. Interleukin-18 (IL-18) is a 
      multifunctional cytokine that augments interferon-gamma production and acts as an 
      important immunomediator in the development of several types of cancer. PATIENTS 
      AND METHODS: This case-control study evaluated the role of IL-18 in NPC at the 
      DNA level by genotyping its promoter polymorphisms at positions -656, -607, and 
      -137 in a Taiwanese population. A total of 176 patients with NPC and age- and 
      gender-matched 352 noncancer controls were included in this study. RESULTS: The 
      CC genotype of the IL-18-607 polymorphism was found to be associated with 
      significantly decreased risks of NPC compared to the AA genotype (crude OR =0.50, 
      95% CI =0.29-0.84, P=0.0093). This significant difference persisted even in the 
      dominant and recessive models. A significantly lower C allele frequency at 
      position -607 was detected in the NPC group(41.8% vs 50.3%; OR =0.77; 95% CI 
      =0.63-1.04, P=0.0089). Regarding IL-18-656 and -137 polymorphisms, there were no 
      differential distributions of their genotypes between the NPC and control groups. 
      After substratification of the subjects according to their smoking, alcohol 
      consumption, and areca chewing status, the genotype distribution of the IL-18-607 
      polymorphism was found to be different only among nonsmokers between the NPC and 
      control subgroups. CONCLUSION: This study suggests that IL-18 plays an important 
      role in the carcinogenesis of NPC in Taiwan and that the genotype-phenotype 
      correlation of IL-18-607 polymorphism and its contribution to NPC need to be 
      investigated further.
FAU - Huang, Chung-Yu
AU  - Huang CY
AD  - Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, 
      Taiwan.
AD  - Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan.
FAU - Chang, Wen-Shin
AU  - Chang WS
AD  - Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, 
      China Medical University Hospital, Taichung, Taiwan, datian@mail.cmuh.org.tw.
FAU - Tsai, Chia-Wen
AU  - Tsai CW
AD  - Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, 
      China Medical University Hospital, Taichung, Taiwan, datian@mail.cmuh.org.tw.
FAU - Hsia, Te-Chun
AU  - Hsia TC
AD  - Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, 
      China Medical University Hospital, Taichung, Taiwan, datian@mail.cmuh.org.tw.
FAU - Shen, Te-Chun
AU  - Shen TC
AD  - Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, 
      China Medical University Hospital, Taichung, Taiwan, datian@mail.cmuh.org.tw.
FAU - Bau, Da-Tian
AU  - Bau DT
AD  - Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, 
      China Medical University Hospital, Taichung, Taiwan, datian@mail.cmuh.org.tw.
AD  - Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 
      Taiwan, datian@mail.cmuh.org.tw.
AD  - Department of Bioinformatics and Medical Engineering, Asia University, Taichung, 
      Taiwan, datian@mail.cmuh.org.tw.
FAU - Shui, Hao-Ai
AU  - Shui HA
AD  - Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20181031
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6217138
OTO - NOTNLM
OT  - IL-18
OT  - Taiwan
OT  - genotype
OT  - nasopharyngeal carcinoma (NPC)
OT  - polymorphism
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/11/23 06:00
MHDA- 2018/11/23 06:01
PMCR- 2018/10/31
CRDT- 2018/11/23 06:00
PHST- 2018/11/23 06:00 [entrez]
PHST- 2018/11/23 06:00 [pubmed]
PHST- 2018/11/23 06:01 [medline]
PHST- 2018/10/31 00:00 [pmc-release]
AID - cmar-10-5199 [pii]
AID - 10.2147/CMAR.S179367 [doi]
PST - epublish
SO  - Cancer Manag Res. 2018 Oct 31;10:5199-5207. doi: 10.2147/CMAR.S179367. 
      eCollection 2018.